30 March 2007
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection
Antonio Tursi, Walter Elisei, Giovanni Brandimarte, Gian Marco Giorgetti, Maria Ester Modeo, Fabio AielloMed Sci Monit 2007; 13(4): CR187-190 :: ID: 481102
Abstract
Background: Up to 35% of H. Pylori-positive patients remain infected after a first eradication attempt. Lactoferrin, a natural anti-bacterial glycoprotein, seems a promising tool in treating H. Pylori infection, but it has never been used in second-line treatment. Material/Methods: A prospective, randomized study was conducted on 70 consecutive patients with persistent H. Pylori infection after failure of the first standard treatment schedule. All patients were randomly treated with ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d.), and tinidazole (500 mg b.d.) without (group A) or with (group B) supplementation of bovine lactoferrin (200 mg b.d.). One month after conclusion of therapy, endoscopy was performed in those patients for whom the examination was clinically relevant. The remaining patients were checked by (13)C-urea breath test. Results: Sixty-seven patients were fully compliant and completed the study (33, i.e. 94.28%, in group A and 34, 97.14%, in group B). One group A patient (2.85%) was excluded for protocol violation and one group B patient (2.85%) was lost to follow-up. H. Pylori eradication was obtained in 31/33 (on intention-to-treat: 88.57%, 95%CI: 87-99%) group A patients and in 33/34 (on intention-to-treat: 94.28%, 95%CI: 86-100%) group B patients (p=ns). 16/68 patients (23.53%) experienced side effects (29.41% in group A and 17.64% in group B, p= 0.05). Conclusions: Lactoferrin supplementation was found effective in reducing side-effect incidence. Moreover, it seems capable of achieving a slight (and not statistically significant) improvement in eradicating H. Pylori when used in second-line treatment.
Keywords: Helicobacter Infections - drug therapy, Tinidazole - therapeutic use, Ranitidine - therapeutic use, Prospective Studies, Lactoferrin - therapeutic use, Helicobacter pylori, Esomeprazole - therapeutic use, Endoscopy, Gastrointestinal, Breath Tests, Bismuth - therapeutic use, Anti-Bacterial Agents - therapeutic use, Amoxicillin - therapeutic use
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Dental Students’ Opinions on Use of Artificial Intelligence: A Survey StudyMed Sci Monit In Press; DOI: 10.12659/MSM.947658
Database Analysis
Defining Effect Size Standards in Temporomandibular Joint and Masticatory Muscle ResearchMed Sci Monit In Press; DOI: 10.12659/MSM.948365
Clinical Research
Evaluating Factors Influencing Periodontal Bone Loss Using Cone Beam Computed Tomography: A Retrospective S...Med Sci Monit In Press; DOI: 10.12659/MSM.947759
Database Analysis
Prognostic Significance and Immune Environment Analysis Using PANoptosis Molecular Clustering in Gastric Ca...Med Sci Monit In Press; DOI: 10.12659/MSM.947710
Most Viewed Current Articles
17 Jan 2024 : Review article 8,225,070
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 703,027
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 30,424
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 24,191
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912